-transparent.png){kind=logo}
The aim of this study was to examine the interrelationships between age, plasma catecholamines, plasma renin activity (PRA) and blood pressure in essential hypertensive (EH) patients. PRA, plasma noradrenaline (NA) and adrenaline (A) were measured in 76 consecutive EH patients (WHO stages 1-2, aged 24-66 years) and in 28 normotensive subjects (aged 25-64 years) studied at rest in supine position after 5 days of normal fixed sodium and potassium intake. Both plasma NA and A were slightly but significantly higher in EH patients (p less than 0.05). While no relationship was found between the various parameters in normotensive subjects, in EH patients, particularly those at WHO stage 2, plasma NA was directly related to mean blood pressure (MBP) (p less than 0.001) and PRA (p less than 0.01). Plasma A was weakly related to MBP (p less than 0.05); PRA was inversely related to age (p less than 0.01) but no relationship was found between NA or A and age. Partial correlation analysis confirmed all these relationships. In fact, NA was related to MBP also considering constant PRA (p less than 0.001) or age (p less than 0.001), and NA was related to PRA also considering constant MBP (p less than 0.01) or age (p less than 0.001). Acute pharmacological alpha- and beta-blockade, with labetalol 100 mg i.v., induced a reduction of MBP which was directly related to basal plasma NA (p less than 0.001). These results support the view that in EH the sympathetic nervous system might be in part responsible for PRA levels and for the severity of hypertension.
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
January 1984,
Mineral and electrolyte metabolism,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
January 1985,
European journal of clinical pharmacology,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
January 1980,
Clinical and experimental hypertension,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
August 1976,
Klinische Wochenschrift,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
February 1977,
The American journal of medicine,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
July 1979,
Klinische Wochenschrift,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
December 1976,
Schweizerische medizinische Wochenschrift,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
February 1980,
The Journal of clinical endocrinology and metabolism,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
January 1980,
Clinical and experimental hypertension,
E Agabiti-Rosei, and
C Alicandri, and
M Beschi, and
M Castellano, and
L Corea, and
P Beggi, and
M Motolese, and
G Muiesan
December 1976,
Clinical science and molecular medicine. Supplement,
